Selected research
Industry Research
Hepatitis Drugs Industry Research Report 2026
Market perspective
The global Hepatitis Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Hepatitis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Hepatitis Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Hepatitis Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Hepatitis Drugs include Johnson & Johnson, Novartis, Merck, GlaxoSmithKline, Abbvie, Vertex Pharmaceuticals, Gilead Sciences, F. Hoffmann-La Roche and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Hepatitis Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hepatitis Drugs Market by Company
Johnson & Johnson
Novartis
Merck
GlaxoSmithKline
Abbvie
Vertex Pharmaceuticals
Gilead Sciences
F. Hoffmann-La Roche
Bristol-Myers Squibb
Achillion Pharmaceuticals
Hepatitis Drugs Segment by Type
VIREAD
VICTRELIS
VEMLIDY
TYZEKA
SOVALDI
OLYSIO
INCIVEK
HEPSERA
EPCLUSA
BARACLUDE
Hepatitis Drugs Segment by Application
Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D
Hepatitis E
Hepatitis Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hepatitis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Hepatitis Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Hepatitis Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Hepatitis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- VIREAD
- VICTRELIS
- VEMLIDY
- TYZEKA
- SOVALDI
- OLYSIO
- INCIVEK
- HEPSERA
- EPCLUSA
- BARACLUDE
Applications
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Hepatitis D
- Hepatitis E
Companies covered
- Johnson & Johnson
- Novartis
- Merck
- GlaxoSmithKline
- Abbvie
- Vertex Pharmaceuticals
- Gilead Sciences
- F. Hoffmann-La Roche
- Bristol-Myers Squibb
- Achillion Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Hepatitis Drugs Market Size (2021-2032)
- 2.2.2 Global Hepatitis Drugs Sales (2021-2032)
- 2.2.3 Global Hepatitis Drugs Market Average Price (2021-2032)
- 2.3 Hepatitis Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 VIREAD
- 2.3.3 VICTRELIS
- 2.3.4 VEMLIDY
- 2.3.5 TYZEKA
- 2.3.6 SOVALDI
- 2.3.7 OLYSIO
- 2.3.8 INCIVEK
- 2.3.9 HEPSERA
- 2.3.10 EPCLUSA
- 2.3.11 BARACLUDE
- 2.4 Hepatitis Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hepatitis A
- 2.4.3 Hepatitis B
- 2.4.4 Hepatitis C
- 2.4.5 Hepatitis D
- 2.4.6 Hepatitis E
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Hepatitis Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Hepatitis Drugs Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Hepatitis Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Hepatitis Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Hepatitis Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Hepatitis Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Hepatitis Drugs, Product Type & Application
- 3.8 Global Manufacturers of Hepatitis Drugs, Established Date
- 3.9 Global Hepatitis Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Johnson & Johnson
- 4.1.1 Johnson & Johnson Company Information
- 4.1.2 Johnson & Johnson Business Overview
- 4.1.3 Johnson & Johnson Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Johnson & Johnson Hepatitis Drugs Product Portfolio
- 4.1.5 Johnson & Johnson Recent Developments
- 4.2 Novartis
- 4.2.1 Novartis Company Information
- 4.2.2 Novartis Business Overview
- 4.2.3 Novartis Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis Hepatitis Drugs Product Portfolio
- 4.2.5 Novartis Recent Developments
- 4.3 Merck
- 4.3.1 Merck Company Information
- 4.3.2 Merck Business Overview
- 4.3.3 Merck Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck Hepatitis Drugs Product Portfolio
- 4.3.5 Merck Recent Developments
- 4.4 GlaxoSmithKline
- 4.4.1 GlaxoSmithKline Company Information
- 4.4.2 GlaxoSmithKline Business Overview
- 4.4.3 GlaxoSmithKline Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 GlaxoSmithKline Hepatitis Drugs Product Portfolio
- 4.4.5 GlaxoSmithKline Recent Developments
- 4.5 Abbvie
- 4.5.1 Abbvie Company Information
- 4.5.2 Abbvie Business Overview
- 4.5.3 Abbvie Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Abbvie Hepatitis Drugs Product Portfolio
- 4.5.5 Abbvie Recent Developments
- 4.6 Vertex Pharmaceuticals
- 4.6.1 Vertex Pharmaceuticals Company Information
- 4.6.2 Vertex Pharmaceuticals Business Overview
- 4.6.3 Vertex Pharmaceuticals Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Vertex Pharmaceuticals Hepatitis Drugs Product Portfolio
- 4.6.5 Vertex Pharmaceuticals Recent Developments
- 4.7 Gilead Sciences
- 4.7.1 Gilead Sciences Company Information
- 4.7.2 Gilead Sciences Business Overview
- 4.7.3 Gilead Sciences Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Gilead Sciences Hepatitis Drugs Product Portfolio
- 4.7.5 Gilead Sciences Recent Developments
- 4.8 F. Hoffmann-La Roche
- 4.8.1 F. Hoffmann-La Roche Company Information
- 4.8.2 F. Hoffmann-La Roche Business Overview
- 4.8.3 F. Hoffmann-La Roche Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 F. Hoffmann-La Roche Hepatitis Drugs Product Portfolio
- 4.8.5 F. Hoffmann-La Roche Recent Developments
- 4.9 Bristol-Myers Squibb
- 4.9.1 Bristol-Myers Squibb Company Information
- 4.9.2 Bristol-Myers Squibb Business Overview
- 4.9.3 Bristol-Myers Squibb Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Bristol-Myers Squibb Hepatitis Drugs Product Portfolio
- 4.9.5 Bristol-Myers Squibb Recent Developments
- 4.10 Achillion Pharmaceuticals
- 4.10.1 Achillion Pharmaceuticals Company Information
- 4.10.2 Achillion Pharmaceuticals Business Overview
- 4.10.3 Achillion Pharmaceuticals Hepatitis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Achillion Pharmaceuticals Hepatitis Drugs Product Portfolio
- 4.10.5 Achillion Pharmaceuticals Recent Developments
5 Global Hepatitis Drugs Market Scenario by Region
- 5.1 Global Hepatitis Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Hepatitis Drugs Sales by Region: 2021-2032
- 5.2.1 Global Hepatitis Drugs Sales by Region: 2021-2026
- 5.2.2 Global Hepatitis Drugs Sales by Region: 2027-2032
- 5.3 Global Hepatitis Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Hepatitis Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Hepatitis Drugs Revenue by Region: 2027-2032
- 5.4 North America Hepatitis Drugs Market Facts & Figures by Country
- 5.4.1 North America Hepatitis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Hepatitis Drugs Sales by Country (2021-2032)
- 5.4.3 North America Hepatitis Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Hepatitis Drugs Market Facts & Figures by Country
- 5.5.1 Europe Hepatitis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Hepatitis Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Hepatitis Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Hepatitis Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Hepatitis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Hepatitis Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Hepatitis Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Hepatitis Drugs Market Facts & Figures by Country
- 5.7.1 South America Hepatitis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Hepatitis Drugs Sales by Country (2021-2032)
- 5.7.3 South America Hepatitis Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Hepatitis Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Hepatitis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Hepatitis Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Hepatitis Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Hepatitis Drugs Sales by Type (2021-2032)
- 6.1.1 Global Hepatitis Drugs Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Hepatitis Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Hepatitis Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Hepatitis Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Hepatitis Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Hepatitis Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Hepatitis Drugs Sales by Application (2021-2032)
- 7.1.1 Global Hepatitis Drugs Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Hepatitis Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Hepatitis Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Hepatitis Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Hepatitis Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Hepatitis Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Hepatitis Drugs Value Chain Analysis
- 8.1.1 Hepatitis Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Hepatitis Drugs Production Mode & Process
- 8.2 Hepatitis Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Hepatitis Drugs Distributors
- 8.2.3 Hepatitis Drugs Customers
9 Global Hepatitis Drugs Analyzing Market Dynamics
- 9.1 Hepatitis Drugs Industry Trends
- 9.2 Hepatitis Drugs Industry Drivers
- 9.3 Hepatitis Drugs Industry Opportunities and Challenges
- 9.4 Hepatitis Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst